Entrada Therapeutics (NASDAQ:TRDA) said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable safety and tolerability and early functional improvement in ...
Clinical Trials Arena on MSN
Entrada’s stock drops as DMD drug’s efficacy falls short
At a 6 mg/kg dose, ENTR-601-44 didn’t elevate dystrophin levels to analyst expectations, or to the baseline change recorded ...
Capricor Therapeutics’ stock has soared by more than 370% after a pivotal trial of its Duchenne muscular dystrophy (DMD) cell therapy candidate met its endpoints. The Phase III HOPE-3 trial ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 ...
Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients. Delandistrogene moxeparvovec ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results